Themis Medicare Limited has informed the Exchange regarding a press release dated February 16, 2023, titled "Themis Medicare announces DCGI approval of Remifentanil Hydrochloride 1mg/2mg for injection for import and marketing.".
Press Release Feb 17 2023
Filed with NSE ·
6ix hasn’t read this filing yet.
Themis Medicare Limited on 6ix
Earlier from Themis Medicare
- Press Release Jan 03 2023
- Press Release Nov 08 2022
- Press Release Oct 06 2022
- Press Release May 18 2022
- Press Release Mar 21 2022
Later from Themis Medicare
All Themis Medicare news releasesFollow Themis Medicare into a list and get an email when it puts out news.
Follow Themis Medicare